Table 2 Current status of regeneration-related clinical trials of biologics and small molecules targeting the Wnt/β-catenin pathway
Name/company | Target | Agent | Conditions | Clinical phase |
|---|---|---|---|---|
Wnt3a (China Medical University Hospital) | FZDs | Native Wnt3a | Primary Disease | recruiting |
AMG785 (Amgen) | Sclerostin | mAb | Bone Fracture Healing, Osteoporosis | II |
Valproic acid (Seoul National University Hospital) | GSK-3β | Valproic acid | Androgenetic Alopecia | II |
| Â | Male Pattern Baldness | Â | ||
AMG 162 (Amgen) | Dkk1 | mAb | Osteoporosis | II |
HSC (Histogen) | multiple | Wnt7a-containing complex | Androgenetic Alopecia | II |